We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Serological Test Differentiates Zika from Dengue Infections

By LabMedica International staff writers
Posted on 26 Jan 2017
Zika virus (ZIKV) is an emerging mosquito-transmitted flavivirus currently causing large epidemics in South and Central America as well as in the Caribbean, presenting a global public health emergency.

Zika is increasingly posing a risk in other parts of the world and it is difficult to differentiate clinically from infections with dengue and chikungunya viruses, which are endemic in the same geographical regions. More...
In laboratory testing, serology is an important supplement to direct detection and provides a much longer diagnostic window.

European scientists led by those at the Institute for Experimental Immunology analyzed serum samples from 27 patients who had tested positive for ZIKV RNA by reverse transcription polymerase chain reaction (RT-PCR); Samples from a further 85 patients had been pre-characterized by EUROIMMUN’s anti-ZIKV indirect immunofluorescence assay based on whole virus antigen, showing reactivity for anti-ZIKV immunoglobulin M (IgM) and/or IgG; 26 travelers returning from endemic area; and 59 residents in ZIKV-endemic areas. Anti-Zika Virus IgM and IgG enzyme-linked immunosorbent assay ELISA (EUROIMMUN) were tested.

In 17 RT-PCR confirmed Zika specimens collected at least six days after symptom onset, the ELISA sensitivity amounted to 59%, for IgM, 88% for IgG and 100% for IgM/IgG. In the suspected Zika cases, the combined sensitivity was 90%. In an additional investigation using samples from 31 patients with RT-PCR confirmed Zika virus infections (follow-up samples taken 7-10 days after positive RT-PCR result); the ELISA demonstrated a sensitivity of 100% for IgM/IgG. The specificity of the ELISA with respect to the blood donors was 99.8%. Cross reactivity with high-level anti-dengue virus antibodies was not detectable. Among 252 patients with potentially cross-reactive antibodies, overall anti-Zika positive rates were 0.8% for IgM and 0.4% for IgG.

The authors concluded that the ELISA provided exceptionally high specificity and avoids the cross reactivity typically associated with tests based on whole virus antigens or viral glycoproteins. The anti-Zika virus ELISA is suitable for acute diagnostics as well as for monitoring purposes, e.g., in prenatal diagnostics, screening of donated blood and epidemiological studies. With its high-throughput format and automatability, the ELISA can be employed in routine laboratories in endemic settings. The study was published on December 16, 2016, in the journal Eurosurveillance.


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Staining System
RAL DIFF-QUIK
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The new RABTA sets a high standard in laboratory diagnostics (Photo courtesy of Randox)

Pioneering Analyzer with Advanced Biochip Technology Sets New Standard in Lab Diagnostics

A state-of-the-art analyzer combines advanced technology with exceptional efficiency to meet the demanding needs of modern laboratories. Randox Toxicology (Antrim, Ireland) has launched its pioneering... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.